SOMAÍ Pharmaceuticals

SOMAÍ Pharmaceuticals Somai is fast becoming one of the most recognized and well-developed pharmaceutical brands in the EU.

A leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio Somai Pharmaceuticals LTD is a European pharmaceutical and biotech company centered on manufacturing in Lisbon, Portugal and distribution of EU GMP-certified cannabinoid-containing pharmaceuticals throughout the European Union and globally. Somai emphasizes scientific pharmacology applications with EU-GMP standards to deliver treatments to the endocannabinoid system, effectively and with consistency across all markets. Somai's product development knowledge was honed in the competitive American market, and is the largest and most advanced cannabinoid manufacturing facility across legal European markets producing medicines products and registered API's. Somai has brought together an all-star team of scientists and KOL's from around the world with various clinical experiences to guide Somai's product development and acceptance globally. Somai stresses education and continual R&D, which started from the USA as transformative developments, to help EU doctors and patients properly diagnose and treat the individual indications by providing variable dosage choices. Somai’s primary goal is producing the most advanced products with the most innovative delivery methods to create maximum bioavailability and healing for patients. As a global biotech player concentrating on cannabinoids, Somai has a unique pipeline of current and future products that will be on the market starting in late 2022. They already boast one of the largest IP (Intellectual Property) vaults of APIs that weren’t accessible to Europe until recently. Somai’s near term products conform to the highest standards of herbal medicine (ACM) and specialized cannabinoid API’s for R&D, but also keeps a steady eye on the horizon of future clinical trials for their proprietary pipeline, setting it up to be well positioned for the next decade.

airobrands official, together with SOMAÍ today announced the launch of the Airo Medical Inhalation Device — one of the f...
24/03/2026

airobrands official, together with SOMAÍ today announced the launch of the Airo Medical Inhalation Device — one of the first CE-certified cannabis medical inhalation devices available in Europe — across pharmacy channels in the German-regulated medical cannabis market.

The system combines the CE-certified Airo Medical Inhalation Device, developed in collaboration with Jupiter Research, with SOMAÍ Pharmaceutical’s EU-GMP-purified inhalation extracts, creating standardized medical options for prescription-based cannabinoid therapies.

“Cannabis extracted products are now entering the medical device phase, allowing popular delivery methods like vaporizers to reach more demographics,” said .sassano.37, Founder and Interim CEO of SOMAÍ. “European and global medical patients are becoming increasingly aware of the benefits of cannabis extracts, and they are now being offered a wider range of dosing options to address their needs and medical indications. We don’t just sell devices to pharmacies; we have created an end-to-end educational and training loop to make the right products and are bringing patient choice to a new age of medical-grade selection for extracts.”

“We are proud to enter Germany as our first European medical market and to support patients with high-quality medical products,” said Richard Yost, CEO of Airo Brands. “By working closely with physicians and pharmacies, our goal is to deliver precise, dependable formulations through a technology-forward inhalation platform. Together with our partners, we are helping advance the standard for pharmaceutical-grade quality in regulated medical markets.

Read the full news here: https://www.einpresswire.com/article/901272299/airo-medical-inhalation-device-launches-in-germany-with-soma-eu-gmp-inhalation-extracts

20/03/2026

Every batch starts here. 🌱
In our mother room, healthy plants are the foundation of consistent medical cannabis production.

Dr. Nigel Gale, Director of Grow & Production, explains why quality starts at the source.

🔹 International Women’s Day | 8 MarchIn the medical cannabis and pharma space, progress doesn’t happen by accident — it ...
08/03/2026

🔹 International Women’s Day | 8 March

In the medical cannabis and pharma space, progress doesn’t happen by accident — it happens because talented women push science forward, raise the bar for quality, and keep patient needs at the center of every decision.

At SOMAÍ, we’re proud to work alongside women across QA, QC, R&D, cultivation, manufacturing, regulatory, supply chain, commercial teams, and leadership — shaping how cannabinoid-based medicines are developed, produced, and delivered with consistency and care.

🔹 What this day means in our industry

- Better representation in leadership and decision-making
- More diverse perspectives in clinical and product development
- Stronger standards across quality, compliance, and patient communication
- A healthier, more inclusive workplace — and a better patient journey

Today we celebrate the women of SOMAÍ and the wider community — and we stay committed to building an industry where opportunities are real, voices are heard, and innovation benefits everyone.

💙 Happy International Women’s Day.

This March, Michael Sassano, SOMAÍ’s Founder, will be traveling across key markets to strengthen partnerships, support c...
03/03/2026

This March, Michael Sassano, SOMAÍ’s Founder, will be traveling across key markets to strengthen partnerships, support current activities, and keep expanding patient access to regulated cannabinoid-based medicines:

•⁠ ⁠⁠Bangkok 1-7 March
•⁠ ⁠⁠Melbourne 7-14 March
•⁠ ⁠⁠Brisbane 14-21 March
•⁠ ⁠⁠Portugal 21-26 March
•⁠ ⁠⁠Italy 26 March - 1 April

As SOMAÍ, our focus remains clear:

🔹 Expanding our global distribution footprint across established and emerging medical markets
🔹 Delivering the largest and most advanced EU-GMP-certified cannabinoid-containing pharmaceutical extract portfolio
🔹 Advancing innovation and consistency through new formulations built for real-world patient needs

If you’re in any of these markets and would like to connect with Michael and the team, reach out: hello@somaipharma.eu

🔵 Celebrating 7 Years of SOMAÍ 🎉Seven years ago, Michael Sassano and George Bellow founded SOMAÍ with a vision: to build...
19/02/2026

🔵 Celebrating 7 Years of SOMAÍ 🎉

Seven years ago, Michael Sassano and George Bellow founded SOMAÍ with a vision: to build a globally leading pharmaceutical company that would shape the future of EU-GMP cannabinoid-based medicine.

Since then, SOMAÍ has:

🔷 Built a state-of-the-art EU-GMP manufacturing facility
🔷 Achieved EU-GMP licensing within just one year
🔷 Grown into a vertically integrated Multi-Country Operator (MCO) with a presence across Europe, the UK, APAC, and beyond
🔷 Established NovaSoma, our advanced indoor cultivation facility in Lisbon, operating under strict pharmaceutical and environmental controls
🔷 Developed one of the most comprehensive EU-GMP-certified extract portfolios
🔷 Launched multiple product lines, including Essentials, Origins, Senses, and Inhalation Oils
🔷 Advanced scientific research and strategic global partnerships

From a bold idea to a global pharmaceutical platform, SOMAÍ continues to raise the standard for cannabinoid-based medicines — combining cultivation excellence, EU-GMP precision, and international distribution expertise.

Thank you to our team, partners, and patients for being part of this journey.

Here’s to the next chapter. 🌐

SOMAÍ today announced a strategic partnership with KISEKI PLANT FACTORY to support the global distribution of KISEKI’s m...
17/02/2026

SOMAÍ today announced a strategic partnership with KISEKI PLANT FACTORY to support the global distribution of KISEKI’s medicinal cannabis flower across SOMAÍ’s international medical markets.

Through this collaboration, KISEKI’s medicinal cannabis products will become available for the first time in the UK, leveraging SOMAÍ’s established regulatory infrastructure and pharmaceutical distribution network. This milestone represents one of the first introductions of a Japanese-origin cannabis brand into Western prescription markets. The partnership will continue to expand in phases, aligned with applicable market authorization processes and regulatory requirements.

“Japanese quality is the result of precise plant-factory engineering, disciplined cultivation processes, and carefully selected genetics,” said Kohei Yamada, Founder and CEO of KISEKI PLANT FACTORY (THAILAND) Co., Ltd. “We are proud to collaborate with SOMAÍ to bring our medicinal cannabis to patients worldwide through a partner that understands regulated medical markets.”

“This collaboration reflects SOMAÍ’s role in working to distribute various craft indoor brands through its global distribution platform,” said Sassano, Founder and Interim CEO of SOMAÍ. “SOMAÍ’s ability to navigate EU-GMP regulatory frameworks to commercialization of unique international brands demonstrates careful thought to reach many demographics in the medical community through diversified cultural offerings that meet the high expectations of regulators, prescribers, and patients worldwide.”

Read the full news: https://www.einpresswire.com/article/892881634/soma-partners-with-japan-s-kiseki-to-introduce-japanese-quality-medicinal-cannabis-to-global-medical-markets

We’re pleased to introduce Inês Lima, a new Regulatory Affairs Manager & Technical Director of Wholesale Distribution at...
10/02/2026

We’re pleased to introduce Inês Lima, a new Regulatory Affairs Manager & Technical Director of Wholesale Distribution at SOMAÍ.

With a background in Pharmaceutical Sciences, Inês has been dedicated to medical cannabis since the beginning of her career. Trained in GMP, GDP, and ISO 9001, she combines academic expertise with hands-on experience in pharmaceutical quality systems and has played an active role in the sector’s regulatory development in Portugal.

In her role at SOMAÍ, Inês leads regulatory engagement, audits, and quality systems across the supply chain — ensuring alignment with the highest pharmaceutical standards across national and international markets. Her work plays a central role in supporting compliant growth, product differentiation, and sustainable patient access.

“SOMAÍ stands out not only for its rigor and quality standards, but also for continuous innovation and increasingly personalized patient access. It is an honour to be part of an organisation that raises the bar for quality and science in medical cannabis,” Inês shared.

With a strong focus on patients, science, and continuous improvement, Inês sees SOMAÍ further consolidating its position as a global reference in cannabinoid-based medicines — advancing innovation while maintaining uncompromising regulatory excellence.

Welcome to the team, Inês.

06/02/2026

Designed for reliable onset when timing matters.

06/02/2026

Designed for reliable onset when timing matters.



🔵 We’re Hiring in Australia 🇦🇺SOMAÍ is expanding its global footprint and we’re looking for an experienced Brand Manager...
03/02/2026

🔵 We’re Hiring in Australia 🇦🇺

SOMAÍ is expanding its global footprint and we’re looking for an experienced Brand Manager to lead and grow our presence in the Australian medical cannabis market, balancing growth objectives with strict regulatory requirements.

🔹 Lead go-to-market strategy and product launches
🔹 Develop compliant marketing and educational materials for HCPs
🔹 Manage digital campaigns, CRM activity, and content calendars
🔹 Work closely with global teams while owning local ex*****on

100% remote | High-impact role | Global support

Apply here: https://www.seek.com.au/job/89979138

We’re heading to Brisbane!SOMAÍ is a Bronze Sponsor of UIC 2026 and we’ll be on the expo floor all conference long.Be su...
29/01/2026

We’re heading to Brisbane!

SOMAÍ is a Bronze Sponsor of UIC 2026 and we’ll be on the expo floor all conference long.

Be sure to catch CEO Michael Sassano’s talk on our latest scientific publications, and then swing by our booth to learn from Sam, Renee & Judi.

Catch you February 26-28.

SOMAÍ today announced that it has received official approval from INFARMED, Portugal’s National Authority of Medicines a...
20/01/2026

SOMAÍ today announced that it has received official approval from INFARMED, Portugal’s National Authority of Medicines and Health Products, to commercialize three of its medical cannabis products in Portugal, and also received independently a Portuguese GDP distribution license that enables direct commercialization and supply.

This market authorization ACM and distribution license approval marks a significant milestone for SOMAÍ, enabling the company to supply the Portuguese medical cannabis market with EU-GMP-certified cannabinoid medicines manufactured in Portugal, in full compliance with national and European regulatory standards.

“This approval represents an important moment for SOMAÍ and for Portugal’s medical cannabis ecosystem,” said Sassano, Founder and Interim CEO of SOMAÍ. “Having an official medical market-authorized product in Portugal and the EU is another milestone accomplished that will supply Portuguese patients, but the bigger picture is that SOMAÍ has already invested significantly in developing comprehensive regulatory dossiers that can access the hardest medical markets in European and global markets, including Spain, France, Poland, New Zealand, and other strictly medical markets. SOMAÍ's investment in dossiers further reinforces our strategy to reach all cannabis markets and provide access to our extract portfolio to patients in all approved markets.”

Read the full news here: https://www.einpresswire.com/article/884621464/soma-secures-product-and-distribution-authorization-in-portugal

Address

Brisbane, QLD

Website

Alerts

Be the first to know and let us send you an email when SOMAÍ Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to SOMAÍ Pharmaceuticals:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category